Premium
Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
Author(s) -
PérezPersona Ernesto,
Mateo Gema,
GarcíaSanz Ramón,
Mateos MaríaVictoria,
De Las Heras Natalia,
De Coca Alfonso García,
Hernández José M.,
Galende Josefina,
MartínNuñez Guillermo,
Bárez Abelardo,
Alonso José M.,
Martín Alejandro,
LópezBerges Consuelo,
Orfao Alberto,
San Miguel Jesús F.,
Vidriales MaríaBelén
Publication year - 2010
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07929.x
Subject(s) - immunophenotyping , monoclonal gammopathy of undetermined significance , multiple myeloma , bone marrow , medicine , flow cytometry , monoclonal , hazard ratio , pathology , monoclonal antibody , oncology , immunology , antibody , confidence interval
Summary The present study explored the impact of two novel criteria; having >95% abnormal plasma cells by flow cytometry at diagnosis and the evolving subtype of the disease, as predictors of progression in 61 smouldering multiple myeloma (SMM) and 311 monoclonal gammopathy of unknown significance (MGUS) patients. Although both criteria were of prognostic value, the risk of progression was better identified by immunophenotyping [Hazard Ratio (HR) 6·2 and 17·2 for SMM and MGUS, respectively] than evolving subtype, which had independent prognostic value only in MGUS (HR 3·6). Immunophenotyping discriminated the different risk of progression within the evolving and non‐evolving subgroups of SMM ( P = 0·01) and MGUS ( P < 0·001).